Cargando…
The efficacy and safety of moxibustion for chronic fatigue syndrome: A protocol for systematic review and meta-analysis
BACKGROUND: The pathogenesis of chronic fatigue syndrome (CFS) is not clear. The main purpose of treatment is to improve autoimmune function and relieve fatigue symptoms. Moxibustion is often used to treat diseases caused by low autoimmunity, especially in relieving fatigue symptoms. It is a superio...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104202/ https://www.ncbi.nlm.nih.gov/pubmed/33950958 http://dx.doi.org/10.1097/MD.0000000000025742 |
_version_ | 1783689443395239936 |
---|---|
author | Xue, Kaiyang Wang, Yanping Wang, Xianzhu Chen, Pingnan Xiao, Caihong Fu, Jing Cui, Jin |
author_facet | Xue, Kaiyang Wang, Yanping Wang, Xianzhu Chen, Pingnan Xiao, Caihong Fu, Jing Cui, Jin |
author_sort | Xue, Kaiyang |
collection | PubMed |
description | BACKGROUND: The pathogenesis of chronic fatigue syndrome (CFS) is not clear. The main purpose of treatment is to improve autoimmune function and relieve fatigue symptoms. Moxibustion is often used to treat diseases caused by low autoimmunity, especially in relieving fatigue symptoms. It is a superior therapy for CFS in traditional Chinese medicine. At present, there is a lack of the high level clinical evidence to support the moxibustion in the treatment of CFS, so this study will systematically review and analyze the currently available randomized controlled trials to evaluate the efficacy and safety of moxibustion in the treatment of CFS. METHODS: We will systematically search PubMed, EMBASE, Cochrane library, Sinomed, CNKI, VIP, and Wanfang Database, ClinicalTrials.gov and Chinese Clinical Trial Registry will also be searched. The time range for the search will be from database activation to March 31, 2021. The randomized controlled trials (RCTs) associated with moxibustion for CFS will be included, regardless of language. We will use the standard proposed in Cochrane Handbook 5.1.0 to assess the bias risk of a single RCT. The main outcome index of the study is Fatigue Assessment Instrument (FAI), secondary outcome indexes will include Fatigue Scale -14 (FS-14), Fatigue Severity Scale (FSS), Pittsburgh sleep quality index (PSQI), natural killer (NK) cells, interleukin- 2 (IL-2), T lymphocyte subsets (CD(4)(+), CD(8)(+)), cure rate, total efficiency and adverse reactions. The random effect model meta was used to analyze the effect data of a single RCT. Heterogeneity will be measured by Cochran Q test and I-squared statistics. We will use 2 subgroup analyses to explore the source of heterogeneity. RCTs with high bias risk was excluded and adjustment effect model was used for sensitivity analysis to test the robustness of the meta-analysis results. The publication bias included in RCTs will be assessed by funnel plot and Egger test. RESULTS: This study will objectively and comprehensively evaluate the efficacy and safety of randomized controlled trials of moxibustion in the treatment of chronic fatigue syndrome, and the results will be submitted to peer-reviewed journals for publication. CONCLUSION: This systematic review will provide clinicians with the latest high-quality evidence for the use of moxibustion in the treatment of chronic fatigue syndrome. INPLASY REGISTRATION NUMBER: INPLASY202140063. |
format | Online Article Text |
id | pubmed-8104202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-81042022021-05-10 The efficacy and safety of moxibustion for chronic fatigue syndrome: A protocol for systematic review and meta-analysis Xue, Kaiyang Wang, Yanping Wang, Xianzhu Chen, Pingnan Xiao, Caihong Fu, Jing Cui, Jin Medicine (Baltimore) 3800 BACKGROUND: The pathogenesis of chronic fatigue syndrome (CFS) is not clear. The main purpose of treatment is to improve autoimmune function and relieve fatigue symptoms. Moxibustion is often used to treat diseases caused by low autoimmunity, especially in relieving fatigue symptoms. It is a superior therapy for CFS in traditional Chinese medicine. At present, there is a lack of the high level clinical evidence to support the moxibustion in the treatment of CFS, so this study will systematically review and analyze the currently available randomized controlled trials to evaluate the efficacy and safety of moxibustion in the treatment of CFS. METHODS: We will systematically search PubMed, EMBASE, Cochrane library, Sinomed, CNKI, VIP, and Wanfang Database, ClinicalTrials.gov and Chinese Clinical Trial Registry will also be searched. The time range for the search will be from database activation to March 31, 2021. The randomized controlled trials (RCTs) associated with moxibustion for CFS will be included, regardless of language. We will use the standard proposed in Cochrane Handbook 5.1.0 to assess the bias risk of a single RCT. The main outcome index of the study is Fatigue Assessment Instrument (FAI), secondary outcome indexes will include Fatigue Scale -14 (FS-14), Fatigue Severity Scale (FSS), Pittsburgh sleep quality index (PSQI), natural killer (NK) cells, interleukin- 2 (IL-2), T lymphocyte subsets (CD(4)(+), CD(8)(+)), cure rate, total efficiency and adverse reactions. The random effect model meta was used to analyze the effect data of a single RCT. Heterogeneity will be measured by Cochran Q test and I-squared statistics. We will use 2 subgroup analyses to explore the source of heterogeneity. RCTs with high bias risk was excluded and adjustment effect model was used for sensitivity analysis to test the robustness of the meta-analysis results. The publication bias included in RCTs will be assessed by funnel plot and Egger test. RESULTS: This study will objectively and comprehensively evaluate the efficacy and safety of randomized controlled trials of moxibustion in the treatment of chronic fatigue syndrome, and the results will be submitted to peer-reviewed journals for publication. CONCLUSION: This systematic review will provide clinicians with the latest high-quality evidence for the use of moxibustion in the treatment of chronic fatigue syndrome. INPLASY REGISTRATION NUMBER: INPLASY202140063. Lippincott Williams & Wilkins 2021-05-07 /pmc/articles/PMC8104202/ /pubmed/33950958 http://dx.doi.org/10.1097/MD.0000000000025742 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | 3800 Xue, Kaiyang Wang, Yanping Wang, Xianzhu Chen, Pingnan Xiao, Caihong Fu, Jing Cui, Jin The efficacy and safety of moxibustion for chronic fatigue syndrome: A protocol for systematic review and meta-analysis |
title | The efficacy and safety of moxibustion for chronic fatigue syndrome: A protocol for systematic review and meta-analysis |
title_full | The efficacy and safety of moxibustion for chronic fatigue syndrome: A protocol for systematic review and meta-analysis |
title_fullStr | The efficacy and safety of moxibustion for chronic fatigue syndrome: A protocol for systematic review and meta-analysis |
title_full_unstemmed | The efficacy and safety of moxibustion for chronic fatigue syndrome: A protocol for systematic review and meta-analysis |
title_short | The efficacy and safety of moxibustion for chronic fatigue syndrome: A protocol for systematic review and meta-analysis |
title_sort | efficacy and safety of moxibustion for chronic fatigue syndrome: a protocol for systematic review and meta-analysis |
topic | 3800 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104202/ https://www.ncbi.nlm.nih.gov/pubmed/33950958 http://dx.doi.org/10.1097/MD.0000000000025742 |
work_keys_str_mv | AT xuekaiyang theefficacyandsafetyofmoxibustionforchronicfatiguesyndromeaprotocolforsystematicreviewandmetaanalysis AT wangyanping theefficacyandsafetyofmoxibustionforchronicfatiguesyndromeaprotocolforsystematicreviewandmetaanalysis AT wangxianzhu theefficacyandsafetyofmoxibustionforchronicfatiguesyndromeaprotocolforsystematicreviewandmetaanalysis AT chenpingnan theefficacyandsafetyofmoxibustionforchronicfatiguesyndromeaprotocolforsystematicreviewandmetaanalysis AT xiaocaihong theefficacyandsafetyofmoxibustionforchronicfatiguesyndromeaprotocolforsystematicreviewandmetaanalysis AT fujing theefficacyandsafetyofmoxibustionforchronicfatiguesyndromeaprotocolforsystematicreviewandmetaanalysis AT cuijin theefficacyandsafetyofmoxibustionforchronicfatiguesyndromeaprotocolforsystematicreviewandmetaanalysis AT xuekaiyang efficacyandsafetyofmoxibustionforchronicfatiguesyndromeaprotocolforsystematicreviewandmetaanalysis AT wangyanping efficacyandsafetyofmoxibustionforchronicfatiguesyndromeaprotocolforsystematicreviewandmetaanalysis AT wangxianzhu efficacyandsafetyofmoxibustionforchronicfatiguesyndromeaprotocolforsystematicreviewandmetaanalysis AT chenpingnan efficacyandsafetyofmoxibustionforchronicfatiguesyndromeaprotocolforsystematicreviewandmetaanalysis AT xiaocaihong efficacyandsafetyofmoxibustionforchronicfatiguesyndromeaprotocolforsystematicreviewandmetaanalysis AT fujing efficacyandsafetyofmoxibustionforchronicfatiguesyndromeaprotocolforsystematicreviewandmetaanalysis AT cuijin efficacyandsafetyofmoxibustionforchronicfatiguesyndromeaprotocolforsystematicreviewandmetaanalysis |